GlobeNewsWire · ACR · November 6, 2026

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

Get the app for more

Explore stock news, insights and company research.